ABBV vs. HALO: AbbVie vs. Halozyme Therapeutics Stock Comparison
How do AbbVie (ABBV) and Halozyme Therapeutics (HALO) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
AbbVie (ABBV) and Halozyme Therapeutics (HALO) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
| Profile Item | ABBV | HALO |
|---|---|---|
| Name | AbbVie Inc. | Halozyme Therapeutics Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 514.92 billion USD | 11.81 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | Nasdaq |
| Listing Date | January 2, 2013 | March 16, 2004 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | ABBV | HALO |
|---|---|---|
| Total Return (1Y) | 37.33% | 50.94% |
| Total Return (3Y, Annualized) | 32.74% | 41.08% |
| Total Return (5Y, Annualized) | 24.73% | 21.68% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | ABBV | HALO |
|---|---|---|
| Volatility (1Y, Annualized) | 25.65% | 41.19% |
| Beta (5Y) | 0.21 | 0.96 |
| Max Drawdown (5Y) | -21.92% | -49.06% |
| Avg. Volume (3M) | 4.76M | 2.29M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | ABBV | HALO |
|---|---|---|
| Sharpe Ratio (1Y) | 1.29 | 1.13 |
| Sortino Ratio (1Y) | 2.02 | 1.78 |
Profitability
ROE (TTM)
Capital efficiency shows on one side only: Halozyme Therapeutics (HALO) earns 216.38% on shareholders’ equity, ranked against its industry; AbbVie (ABBV) has no ROE this period.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
- ABBV
- --
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
216.38%
- HALO
- 216.38%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Halozyme Therapeutics (HALO) at 26.93% keeps the most of each sales dollar — above its industry’s net margin range — and AbbVie (ABBV) at 15.67% also retains a top-quartile share.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
15.67%
- Max
- 18.05%
- ABBV
- 15.67%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
26.93%
- HALO
- 26.93%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both AbbVie (ABBV) at 39.59% and Halozyme Therapeutics (HALO) at 59.84% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
39.59%
- Max
- 83.12%
- ABBV
- 39.59%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
59.84%
- Max
- 83.12%
- HALO
- 59.84%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | ABBV | HALO |
|---|---|---|
| ROE (TTM) | -- | 216.38% |
| ROA (TTM) | 10.74% | 22.42% |
| Net Margin (TTM) | 15.67% | 26.93% |
| Operating Margin (TTM) | 39.59% | 59.84% |
| Gross Margin (TTM) | 73.72% | 77.74% |
Growth
Revenue Growth
Both AbbVie (ABBV) at 8.57% and Halozyme Therapeutics (HALO) at 37.55% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Both AbbVie (ABBV) at -0.84% and Halozyme Therapeutics (HALO) at -25.36% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.
Growth Metrics
| Metric | ABBV | HALO |
|---|---|---|
| Revenue Growth (YoY) | 8.57% | 37.55% |
| Revenue Growth (3Y CAGR) | 1.75% | 28.38% |
| EPS Growth (YoY) | -0.84% | -25.36% |
| EPS Growth (3Y CAGR) | -29.03% | 21.14% |
Financial Strength
Current Ratio (MRQ)
Halozyme Therapeutics (HALO) at 3.88 keeps current ratio within its industry’s typical mid-range, while AbbVie (ABBV) at 0.87 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for ABBV.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.87
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- ABBV
- 0.87
- Min
- 0.10
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.88
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- HALO
- 3.88
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Neither AbbVie (ABBV) nor Halozyme Therapeutics (HALO) reports a debt-to-equity ratio value for this period, so a direct comparison isn’t possible.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
- ABBV
- --
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
- HALO
- --
Financial Strength Metrics
| Metric | ABBV | HALO |
|---|---|---|
| Current Ratio (MRQ) | 0.87 | 3.88 |
| Debt / Equity (MRQ) | -- | -- |
| Net Debt / EBITDA | 2.21 | 1.90 |
Dividends
Dividend Yield (TTM)
Halozyme Therapeutics (HALO) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile AbbVie (ABBV) reports a yield of 2.40%, ranking against industry peers normally.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.40%
- ABBV
- 2.40%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- HALO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
AbbVie (ABBV) reports payout ratio above 100% at 117.35%, meaning dividends exceeded current-period earnings; Halozyme Therapeutics (HALO) pays no dividend (payout 0.00%).
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
117.35%
- ABBV
- 117.35%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- HALO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | ABBV | HALO |
|---|---|---|
| Dividend Yield (TTM) | 2.40% | 0.00% |
| Dividend Payout Ratio (TTM) | 117.35% | 0.00% |
Valuation
P/E Ratio (TTM)
Halozyme Therapeutics (HALO) at 25.91 is near its industry’s usual P/E ratio, while AbbVie (ABBV) at 50.05 sits in the richer quartile — ABBV needs stronger growth or earnings quality to justify the premium.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
50.05
- Max
- 85.34
- ABBV
- 50.05
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
25.91
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- HALO
- 25.91
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both AbbVie (ABBV) at 7.80 and Halozyme Therapeutics (HALO) at 6.55 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.80
- Max
- 58.18
- Q3
- 25.77
- ABBV
- 7.80
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.55
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- HALO
- 6.55
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Both AbbVie (ABBV) at -112.34 and Halozyme Therapeutics (HALO) at -213.67 report negative P/B ratio values, meaning both companies have negative book equity — neither multiple is meaningful for valuation.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
-112.34
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
- ABBV
- -112.34
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
-213.67
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
- HALO
- -213.67
Valuation Metrics
| Metric | ABBV | HALO |
|---|---|---|
| P/E Ratio (TTM) | 50.05 | 25.91 |
| P/S Ratio (TTM) | 7.80 | 6.55 |
| P/B Ratio (MRQ) | -112.34 | -213.67 |
| Free Cash Flow Yield (TTM) | 3.44% | 3.48% |